Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission

Eliminating MRD — FDA approval of blinatumomab for B-ALL in complete remissionEliminating MRD — FDA approval of blinatumomab for B-ALL in complete remission, Published online: 04 September 2018; doi:10.1038/s41571-018-0087-yThe approval of blinatumomab based on achievement of undetectable minimal residual disease (MRD) in patients with B cell acute lymphoblastic leukaemia in complete remission is the first of its kind and raises important considerations. This drug might improve outcomes in this setting, although considerable evidence is needed to validate the performance of MRD as a surrogate end point and confirm the hypothesis.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research